Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts
Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts
Specialty net revenue increased 19% to $115.64 million, driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT and ONGENTYS for Parkinson's disease.On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, beating the consensus of $0.14.
上周五，Amneal Pharmaceuticals Inc（纳斯达克：AMRX）报告第三季度调整后每股收益为0.16美元，低于一年前的0.19美元，超过了预期的0.14美元。
The company reported sales of $702.47 million, up 13% year-over-year, beating the consensus of $696.80 million.
该公司报告的销售额为70247万美元，同比增长13%，超过了69680万美元的预期。
Generic net revenue increased by 9% to $427.35 million, driven by the strong performance of new product launches and biosimilars.
通用净营业收入增长了9%，达到42735万美元，受新产品推出和生物类似物性能强劲的推动。
Specialty net revenue increased 19% to $115.64 million, driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT and ONGENTYS for Parkinson's disease.
专业净营业收入增长了19%，达到11564万美元，得益于神经学和内分泌学中推广的产品，包括近期推出的用于帕金森病的CREXONt和ONGENTYS。
AvKARE's net revenue increased by 21% to $159.49 million, driven by growth across its distribution and government-label sales channels.
AvKARE的净营业收入增长了21%，达到15949万美元，这得益于其分销和政府标示销售渠道的增长。
Adjusted EBITDA in the third quarter of 2024 was $158 million, an increase of 2% compared to the third quarter of 2023, reflective of strong revenue performance and higher gross margins, partially offset by a $20 million research and development milestone payment associated with the company's exclusive license of Omalizumab during the third quarter of 2024.
2024年第三季度调整后的EBITDA为15800万美元，比2023年第三季度增长2%，这反映了强劲的收入表现和较高的毛利率，部分抵消了2024年第三季度公司独家许可Omalizumab的研发重要阶段付款2000万美元。
"Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth:
“Q3是一个出色的季度，我们在所有业务领域持续推动强劲的财务业绩，并宣布了三项战略举措，以巩固我们的长期增长：
- We launched CREXONT for the treatment of Parkinson's disease.
- We announced our collaboration with Metsera, Inc. to leverage Amneal's expertise and supply next-generation medicines for obesity and metabolic diseases.
- We expanded our deep pipeline by in-licensing a new high-value biosimilar," said Chirag and Chintu Patel, Co-CEOs.
- 我们推出用于帕金森病治疗的CREXONt。”
- 我们宣布与Metsera, Inc. 合作，利用Amneal的专长为肥胖和代谢性疾病供应下一代药物。
- “我们通过授权许可一种新的高价值生物相似药物来扩大我们深厚的管线，” Chirag和Chintu Patel，联合首席执行官说。
Guidance: Amneal has reaffirmed its 2024 revenue guidance of $2.7 billion—$2.8 billion and adjusted EPS of $0.57-$0.63, versus the consensus of $2.76 billion and $0.60, respectively.
指引：Amneal重申其2024年营业收入指引为27-28亿美元，调整后的每股收益为0.57-0.63美元，而市场共识分别为27.6亿美元和0.60美元。
The company expects 2024 adjusted EBITDA of $610 million—$630 million, operating cash flow of $280 million—$320 million and capital expenditures of $60 million—$70 million.
该公司预计2024年调整后的EBITDA为61000万-63000万美元，经营性现金流为28000万-32000万美元，资本支出为6000万-7000万美元。
Price Action: At last check on Friday, AMRX stock down up 4.88% to $8.19 during the premarket session.
价格走势：上周五最后的检查显示，在盘前交易时段，AMRX股价下跌4.88%，至8.19美元。
- Asia Markets Mixed, Europe, Crude Oil, Gold, And Dollar Cool Off – Global Markets Today While US Slept
- 亚洲市场波动，欧洲、wti原油、黄金和美元稳中降温-全球市场今日美国睡觉时
